Premium
A POSSIBLE DIRECT EFFECT OF 24,25‐DIHYDROXYCHOLECALCIFEROL ON THE PARATHYROID GLAND IN PATIENTS WITH CHRONIC RENAL FAILURE
Author(s) -
CHRISTIANSEN C.,
Rødbro P.,
NÆSTOFT J.,
CHRISTENSEN MERETE S.
Publication year - 1981
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1981.tb00660.x
Subject(s) - microgram , medicine , chronic renal failure , endocrinology , hypercalcaemia , calcium , chemistry , biochemistry , in vitro
SUMMARY Seventeen undialysed adult patients with chronic renal failure took part in a controlled study of the effects of 1,25(OH) 2 D 3 and D 3 . After a 6‐month observation period the patients were allocated at random to two groups for 6 months of treatment with either 1,25(OH) 2 D 3 (mean dose 0·5 μg daily) or D 3 (dose 100 μg daily). The treatment was then discontinued and the patients were studied for a further 3 months. In the 1,25(OH) 2 D 3 group the mean serum concentration of 1,25(OH) 2 D rose significantly during treatment, whereas serum concentrations of 25OHD and 24,25(OH) 2 D remained unchanged. In the D 3 group there was a highly significant increase in serum concentrations of 25OHD and 24,25(OH) 2 D, whereas serum 1,25(OH) 2 D remained unchanged. There was a significant fall in serum iPTH in both treatment groups. This fall was unrelated to serum calcium in the D 3 group unlike the findings in the 1,25(OH) 2 D 3 group. The data support previous experimental evidence that serum iPTH can be suppressed by 24,25(OH) 2 D 3 and suggest that this analogue may be of clinical importance in the treatment of chronic renal failure without inducing hypercalcaemia.